Replies to post #436347 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

“Brief Summary:
The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.”

The primary measure was safety:

“Primary Outcome Measures :
Number of patients with adverse events [ Time Frame: 6 months ]

Secondary Outcome Measures :
Number of patients with tumor response [ Time Frame: 18 months ]

Other Outcome Measures:
Number of patients surviving [ Time Frame: 24 months ]
Number of patients surviving without tumor progression [ Time Frame: 24 months ]”

https://www.clinicaltrials.gov/ct2/show/NCT01882946?term=Northwest+Biotherapeutics&rank=2